MedeAnalytics Expands Industry Engagement to Help Health Plans Drive Measurable Performance with AI Mede Analytics, a leader in healthcare performance improvement, has announced its participation in a series of major…
GenSight Biologics Confirms Full-Year 2025 Financial Results in Line with Prior Estimates GenSight Biologics a clinical-stage biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous…
VDYNE Secures FDA IDE Approval to Advance Pivotal TRIVITA1 Trial for Transcatheter Tricuspid Valve Replacement System VDYNE, Inc., a privately held medical device innovator focused on next-generation transcatheter valve therapies,…
Premier Radiology Services Acquires Global Imaging Solutions to Expand Teleradiology and Subspecialty Expertise Premier Radiology Services (Premier) has announced the acquisition of Global Imaging Solutions (GLOBIS), a well-established teleradiology provider…
FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug…
Mosaic Therapeutics Strengthens Leadership with Appointment of Dr. Vince O’Neill as Head of R&D Mosaic Therapeutics, a clinical-stage oncology company focused on developing next-generation combination therapies, has announced the appointment…
Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Advance Breakthrough Lymphedema Technology Sub-Q Bionics, an emerging medical device company focused on transforming the treatment landscape for lymphedema, has successfully closed…
Scholar Rock Resubmits BLA for Apitegromab in SMA Treatment Scholar Rock has announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for…
New ACC.26 Data Strengthen Evidence for Vutrisiran in ATTR-CM and Highlight Zilebesiran’s Potential in Hypertension Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, announced new clinical and real-world findings…
Organigram Shareholders Approve Sanity Group Acquisition and Key Resolutions at 2026 Annual Meeting Organigram Global has announced that its shareholders have overwhelmingly approved the company’s previously disclosed acquisition of Sanity…
TruBridge Delays Reporting to Complete Year-End Audit, Sets New Earnings Release and Call Schedule TruBridge, Inc. has announced a revised schedule for the release of its financial results for the…
Emmaus Life Sciences Announces Full-Year 2025 Financial Results Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company focused on treatments for sickle cell disease, has reported its financial condition and operating…